Introduction
Articular cartilage is a remarkably durable tissue that provides for almost frictionless motion between the articulating surfaces of diarthrodial joints, while protecting the underlying bones from mechanical stresses of normal joint use. Maintaining healthy cartilage is essential to remaining physically active throughout adult life.
The physical demands placed on articular cartilage during loading dictate a uniformly dense biological structure, devoid of blood vessels, lymphatics and innervation. It is comprised primarily of water, extracellular matrix (ECM) and chondrocytes which populate the cartilage at low density. The ECM is a complex network consisting predominately of type II collagen fibers and proteoglycans, which serve to both retain and restrain the matrix water. The level of hydration and the ability of the matrix to control effectively fluid flow determine the capacity of the cartilage to cushion the subchondral bone during loading. The chondrocytes continually synthesize, incorporate and degrade ECM proteins, permitting much of the cartilage matrix to undergo turnover and maintenance. Circumstances that impair chondrocyte function can disrupt the balance of synthesis and catabolism in favor of cartilage degradation, which over time can lead to osteoarthritis (OA).
A consequence of its lack of vascularity is the very limited capacity of articular cartilage for self-repair. In most tissues, injury is associated with a rupture of blood vessels, an influx of cells and bioactive peptides from the blood, and the formation of a hematoma. Undifferentiated mesenchymal progenitor cells migrate into the lesion, differentiate into the local cellular phenotype and synthesize repair tissue. When lesions occur that are limited to the articular cartilage in adults, there is no bleeding and thus no mechanism for the replacement of lost or damaged tissue ( Figure 1 ). Neighboring chondrocytes may respond by local proliferation; however, because they are sequestered in the dense matrix, they do not migrate into the damaged region to fill the void. As such, focal lesions that are limited to the chondral layer usually remain for life. These can often expand with time and use, and lead to the more generalized cartilage loss associated with OA. [1] [2] [3] A repair response can occur when injury extends through the chondral layer to the subchondral bone and underlying vasculature. Local bleeding and fibrin clot formation causes an infiltration of bone marrow-derived cells which synthesize space-filling repair tissue ( Figure 1 ). This may initially heal to resemble hyaline cartilage after 6-8 months, but in the longer term becomes increasingly populated with type I collagen, degenerating to a fibrocartilaginous scar tissue that does not have the appropriate physical and mechanical properties, and ultimately fails. [3] [4] [5] The specialized architecture and limited repair capacity of articular cartilage coupled with the high physical demands on this tissue make it exceedingly difficult to treat medically. There is currently no regimen, either pharmacologic or surgical, that is capable of restoring damaged cartilage to its normal phenotype. It is generally accepted that achieving repair will require the delivery of a space-filling entity composed of cells and/or matrix. But the major challenge is to produce a tissue that can fulfill the stringent mechanical, as well as biological requirements. It is in this respect that gene transfer may serve as a valuable tool.
Candidate cDNAs
Research advances in the fields of embryonic development 6 and molecular and cellular biology have identified a variety of proteins whose biological activities might be harnessed for medical application for cartilage disease and injury. These molecules have a broad range of activities, among which are the capacity to induce mitosis and the synthesis and deposition of cartilage extracellular matrix components by chondrocytes, induction of chondrogenesis by mesenchymal progenitor cells and the ability to inhibit responses to inflammatory stimuli. [7] [8] [9] [10] [11] Sustained, controlled administration of the appropriate protein cocktail to articular tissues could be used to improve approaches to the treatment of injured cartilage. 12 This could occur either by fostering differentiation into and/or maintenance of the appropriate chondrocyte phenotype for synthesis of repair tissue that functionally resembles normal articular cartilage, or by protecting the cartilage from the effects of inflammation. Although recombinant proteins are difficult to apply effectively in vivo, gene delivery provides a mechanism to convert specific target cells into factories capable of sustained protein production. Through the appropriate administration of recombinant vectors and/or genetically modified cells to damaged cartilage, it may be possible to direct healing or regenerative processes toward a favorable outcome.
Among the list of potentially useful cDNAs for cartilage repair are anabolic growth factors of the transforming growth factor (TGF)-b superfamily, [13] [14] [15] including TGF-bs 1-3, 16 several of the bone morphogenetic proteins (BMPs), [17] [18] [19] insulin-like growth factor (IGF)-1, 8, 20, 21 fibroblast growth factors (FGFs) 7, 22 and epidermal growth factor (EGF). 23 Transcription factors such as Sox-9, 24-26 L-Sox 5 and Sox-6 25 that promote chondrogenesis or the maintenance of the chondrocyte phenotype present another class of biologics that may be useful. Signal transduction molecules, such as SMADS, [27] [28] [29] [30] are also known to be important in chondrocyte differentiation. Because these regulatory molecules function intracellularly and cannot be delivered to cells in soluble form, gene transfer is perhaps the only avenue through which they might be directly applied for medical use.
Treatment or prevention of cartilage loss due to OA may also require inhibition of the actions of certain inflammatory cytokines, such as IL-1 and TNFa. These proteins, synthesized by synovial cells and chondrocytes, are found at elevated levels in arthritic joints and are important mediators of cartilage degradation. 10 Administration of proteins that are anti-inflammatory or antierosive, such as interleukin-1 receptor antagonist (IL-1Ra), 31 soluble TNF receptors, or inhibitors of matrix metalloproteinases may be effective in reducing cartilage loss.
From these candidate cDNAs, various combination therapies may also be useful. For example, dual axis Gene therapy in the repair of articular cartilage SB Trippel et al therapy using an anabolic growth factor such as IGF-I and an inhibitor of the catabolic action of inflammatory cytokines such as IL-1Ra, has the potential to control the degradation associated with osteoarthritis and allow partial restoration of the depleted cartilage matrix. As numerous as there are cDNAs with healing and regenerative potential, there are equally as many options for delivering them. Methods currently being explored range from those as simple as direct delivery of a vector to a defect, to synthesis of cartilaginous implants through tissue engineering. The challenge to gene-based treatment strategies is to devise methods that incorporate the correct gene or gene combination with the appropriate vector, delivered to specific target cells within the proper biological context to achieve a meaningful therapeutic response. Toward the treatment and repair of damaged articular cartilage, the three primary candidate cell types to target for genetic modification are synovial lining cells, chondrocytes and mesenchymal stem cells (MSCs).
Gene transfer to cells in the synovial lining
Direct intra-articular injection of a vector or genetically modified cells into the joint space is, at least conceptually, the simplest approach to gene transfer to joint tissues. Following delivery, the vector or cells are distributed throughout the joint space to interact with all available receptive cells and surfaces. Since the synovium lines all internal surfaces of the joint space, except for cartilage, and has a relatively large surface area, suspensions of cells, such as synovial or dermal fibroblasts, that are injected into the joint space engraft almost exclusively in the synovial lining. 32 Furthermore, since this tissue is highly cellular, and there is no membrane separating the resident cells from the synovial fluid, the primary site of vector interaction also occurs in the synovium. Typically, strategies involving direct intra-articular injection of vector or modified cells involve secreted transgene products, where the genetically modified cells in the synovial lining constitutively synthesize and release therapeutic proteins into the joint space which then bathe all available tissues.
Considerable progress has been made toward defining the parameters critical to effective gene transfer to synovium. Recent work has shown that in the absence of immune recognition of foreign ('nonself') transgene products (such as bacterial b-galactosidase, green fluorescent protein (GFP) from jellyfish) or vector-specific antigens, cells lining the joint space are capable of expressing transgene products at relevant levels for greater than 6 months. 33 This provides optimism that in a clinical setting involving immunologically compatible vector systems and homologous transgenes, such sustained transgene expression will also be achieved.
The effectiveness of synovial gene transfer as a method of delivery of therapeutic agents is well documented in research directed toward rheumatoid arthritis, and data are beginning to emerge of its potential for treating OA (see Evans et al, this issue). Mi et al 34 found that delivery of Ad.IGF-1 to the knees of normal rabbits and those with experimental arthritis was capable of stimulating an increase in proteoglycan synthesis in articular cartilage without adverse effects. Frisbie et al 35 found that delivery of an adenovirus encoding the equine homolog of IL-1Ra into the joints of horses with experimental OA resulted in significant clinical improvement in both pain and disease activity, and preservation of articular cartilage. While it is possible to achieve biologically relevant levels of transgene expression by both direct and ex vivo gene transfer to synovium, this approach may not be compatible with many of the pleiotropic protein products considered as candidates for stimulating cartilage repair or regeneration. These agents have the capacity to stimulate undesirable activities in cells of nontarget, collateral tissues. Although there is a report of repair of cartilage lesions in rabbits following ex vivo gene transfer of TGF-b1 to synovium using genetically modified fibroblasts, 36 the consensus among several other studies is that such a procedure can be quite toxic, resulting in severe joint fibrosis, extreme swelling, osteophytes and cartilage degeneration. 37, 38 Similarly, overexpression of BMP-2 in the synovial lining of knees of mice from either direct or ex vivo gene transfer caused the formation of ectopic cartilage throughout the joint capsule and growth of large osteophytes. 39 Given the considerable variability in transgenic expression typically observed among joints following intra-articular injection of recombinant vectors or modified cells, these findings indicate caution when considering cDNAs for use in synovial gene transfer. Selection should favor those that are effective across a broad dose range that can be applied safely by flooding the joint space with large amounts of gene product.
Chondrocytes as targets for gene delivery
Since chondrocytes are the native cell of articular cartilage, they would seem a logical target for genetic modification. However, because of the dense cartilage ECM that surrounds these cells, they have been typically unavailable for genetic modification by direct intraarticular injection of most recombinant vectors. 33, [40] [41] [42] There have been reports of AAV-mediated transduction of chondrocytes in cartilage explants in culture, [43] [44] [45] which has been attributed to the smaller size of the AAV particle relative to other viral systems. However, since AAV does not specifically target chondrocytes following direct injection into the joint, it will similarly transduce receptive cells in the synovium.
Because articular cartilage is aneural and does not signal distress, damage or deterioration in the early phases of disease, there is often considerable articular cartilage substance loss by the time a problem is recognized. In this situation, pharmaceutical agents delivered by gene transfer or by conventional routes will have a difficult time activating the remaining cells to restore the lost articular cartilage tissue. Thus, in many cases, successful cartilage repair will likely require administration of supplemental cells. This, coupled with the inability to specifically target gene delivery to chondrocytes in situ, has caused many laboratories to focus attention to ex vivo approaches. Although laborious, this approach satisfies several important criteria: (i) it provides a means of increasing the local cellularity; (ii) it targets transgenic expression specifically to the site of repair; (iii) free vector particles are not administered to the subject; and (iv) it enables analysis of cells postmodification for levels of transgene expression and Gene therapy in the repair of articular cartilage SB Trippel et al potential safety issues prior to delivery. Furthermore, the emergence of studies of ex vivo gene delivery to chondrocytes has largely coincided with the advent of autologous chondrocyte transplantation (ACT) as a surgical approach to cartilage repair. 46 For this, chondrocytes are isolated from articular cartilage harvested from non-weight-bearing regions; the cells are expanded in culture, then injected beneath a periosteal flap sutured over a cartilage lesion. Thus, a potential benefit of ex vivo gene transfer using chondrocytes is that the technical aspects for the isolation, culture and handling of these cells for large-scale clinical application has already been established.
Chondrocytes cultured in monolayer are receptive to transduction using the more common viral vectors, including adenovirus, [47] [48] [49] oncoretrovirus (MoMLV), 50 VSV-G pseudotyped lentivirus 33 and AAV. 44, 48, 51 Although chondrocytes have been somewhat resistant to transfection with plasmid DNA, formulation with certain commercially available lipid-based reagents such as FuGENE6t 52, 53 and Lipofectint has been found to enhance the efficiency of DNA uptake, as has pretreatment of the cells with hyaluronidase 54 and mild detergent. 55 Similar to gene delivery in most cell types, viral-based vectors are capable of generating far higher levels of transgene expression with greater persistence. However, it has been found by several groups that incorporation of modified chondrocytes into threedimensional culture will increase the longevity of transgenic expression from nonviral, plasmid-based systems. 45, 54 Following genetic modification, chondrocytes in culture are capable of sustained expression of certain transgene products at biologically relevant levels. For example, transfer of cDNAs encoding certain bioactive factors can be used to stimulate anabolic pathways. Delivery by recombinant adenovirus of the cDNAs for TGF-b, 56 ,57 IGF-1, 11,57 BMP-2 57 or BMP-7 58 to monolayer cultures of chondrocytes isolated from experimental animals has been shown to stimulate expression of cartilage matrix genes, resulting in increased synthesis of proteoglycan and collagen type II. TGF-b1, IGF-1 and BMP-2 overexpression was also found to rescue proteoglycan synthesis following pretreatment of the chondrocytes with IL-1, a potent inhibitor of matrix synthesis. 57 The delivery of genes whose products enable maintenance of the phenotype of hyaline cartilage without hypertrophy of the chondrocytes would be highly desirable. In this regard, IGF-1 gene transfer was also found to render chondrocyte cultures resistant to dedifferentiation in monolayer, enabling maintenance of the chondrocytic phenotype for at least 28 days in culture. 59 Similar results have been observed following transfer of human telomerase 60 and connective tissue growth factor/hypertrophic chondrocyte-specific gene product 24 (CTGF/Hcs24) into chondrocyte cultures. 61 From accumulating reports in the literature, it appears that the act of genetic modification either virally or nonvirally does not, in and of itself, adversely affect the physiology of the chondrocyte. Research emphasis has then shifted toward exploring the use of tissue engineering to deliver genetically modified chondrocytes. Indeed, tissue engineering strategies offer several potential advantages. First, lost articular cartilage substance, even when extensive, can be replaced. Second, preservation of the chondrocyte phenotype, or differentiation of nonchondrocytic cells into chondrocytes, is dependent on the cellular environment, and the three-dimensional environment provided by certain scaffolds promotes the chondrocyte phenotype. Third, tissue engineered constructs may have immediate therapeutic benefit; they do not necessarily depend on the relatively slow recreation of articular cartilage substance. A major limitation of conventional tissue engineering approaches to articular cartilage repair is the limited intrinsic mitotic and matrix synthetic activity of the cellular component of the engineered constructs. By combining the respective benefits of gene transfer and tissue engineering, it is reasonable to speculate that a more efficacious treatment for articular cartilage might be achieved than with either method used alone.
Genetically altered chondrocytes retain the ability to attach to and colonize cartilage explants in culture, 47 and following engraftment to the explant surface, are capable of expressing a transgene product at functional levels. Initial studies by Baragi et al 47 showed that in this context, chondrocytes adenovirally transduced to overexpress IL-1 receptor antagonist were resistant to IL-1-induced proteoglycan degradation. Work by Madry et al 62 showed that transplantation of chondrocytes transfected with plasmid DNA encoding IGF-1 onto articular cartilage explants led to significant resurfacing. The IGF-1-expressing chondrocytes were observed to generate tissue that was thicker than that produced by similarly transplanted control cells and was rich in type II collagen and proteoglycan. Additionally, the underlying cells native to the explant showed increased glycosaminoglycan synthesis.
Initial in vivo studies by Kang et al 50 showed that allogenic chondrocytes transduced with a retroviral vector encoding a marker gene, when embedded in a collagen gel and delivered to osteochondral defects in rabbits, could support transgenic expression for several weeks. Similar results have been obtained with chondrocyte-seeded collagen type I matrices following genetic modification of the cells with adenovirus. 63, 64 More recently it was found that transfected chondrocytes incorporated into alginate spheres and implanted into osteochondral defects in rabbit knees would express detectable levels of activity from marker genes from plasmid DNA for as long as 32 days. 45 Together, these studies confirm the feasibility of using chondrocytes as a means of ex vivo gene transfer to cartilage lesions and that prolonged expression of a transgene in vivo (ie X2 weeks) is feasible using commonly available vectors and three-dimensional supports.
Results of efficacy studies are beginning to emerge detailing the effects of genetically modified chondrocytes in cartilage lesions in animal models. Two recent reports have described ex vivo gene transfer to cartilage lesions in the horse using allogenic chondrocytes, adenovirally transduced to express equine IGF-1 65, 66 or BMP-7.
67
Following genetic modification, the cells were incorporated in a matrix of autogenous fibrin implanted into surgically generated 15 mm full-thickness cartilage lesions. In the defects of animals receiving chondrocytes modified with Ad.IGF-1, accelerated cartilage repair was evident. Examination of tissues recovered from biopsies at 4 and 9 weeks postimplantation revealed an increase in the volume of tissue and the expression of Gene therapy in the repair of articular cartilage SB Trippel et al chondrogenic markers. Transgenic IGF-1 expression in the defect was evident at 4 weeks, but rapidly declined thereafter. Associated with this decline was a decrease in the comparative differences in the quality of healing tissue, until 8 months after chondrocyte implantation, when the quality of cartilage repair was similar in defects implanted with transduced chondrocytes compared to those with naive chondrocytes. 65, 66 Delivery of the cDNA for BMP-7 in the same manner also showed advanced early hyaline cartilage repair, with prolific BMP-7 transgene expression at 4 weeks. Tissue markers of hyaline cartilage, including type II collagen, were also evident at 4 weeks and colocalized with regions of BMP-7-expressing cells. Despite acceleration of initial hyaline cartilage formation, long-term evaluation showed a decline in difference between BMP-7-transduced defects and those expressing an irrelevant transgene (cytosine deaminase). Over the 8-month duration of the experiment, expression of endogenous BMP-7 had developed in defects transplanted with BMP-7-expressing chondrocytes, as well as defects transplanted with chondrocytes expressing the irrelevant transgene. Given this information, the constitutive expression of BMP-7 may have been instrumental in the improved healing in both defect types. Overall, the levels of collagen type II and proteoglycan, and the mechanical characteristics of the healing tissue were similar in BMP-7-transduced defects and defects containing cells expressing an irrelevant transgene. 67 To provide insight into the fate of the chondrocytes postdelivery, a portion of each of the previous two studies entailed the use of modified chondrocytes derived from male donors implanted in female recipients. Quantitative PCR was then used to detect the presence of the SRY-gene marker in recovered tissue samples. Analyses from horses at 4, 9 and 32 weeks suggested a substantial early decline in graft cell numbers. With the use of IGF-1, the range of persisting graft cells at 4 weeks was 3-8%. 65, 66 A similar trend was seen with BMP-7 with a variation of 0-28% of transplanted chondrocytes surviving in the defect at 8 months. 67 These results are encouraging in that they demonstrate that genetic modification of chondrocytes can be used to augment cartilage repair processes in a large animal model. They also suggest that the stability of the therapeutic benefit is linked to the persistence of transgene expression. In these studies, the loss of expression was associated with the loss of modified cells over time. Several sources may account for this. In all cases, allogenic cells were used that were modified with first-generation recombinant adenovirus. Both of these factors have the potential to activate immune pathways that could lead to elimination of the implanted cells. It is also possible that the expansion and culture of the chondrocytes in vitro alters their biology, leading to premature turnover or death. These types of issues can be addressed with the use of autologous cells and vectors that do not express native viral proteins, such as AAV or lentivirus.
Gene transfer to chondroprogenitor cells
The use of autologous chondrocytes as a source of cells for ex vivo gene transfer requires an invasive surgical procedure and removal of non-weight-bearing articular cartilage, of which there is a very limited supply. Although chondrocytes can be readily expanded in culture, there may be problems with loss of phenotype following multiple passages. 68 Alternatively, mesenchymal progenitor cells, also referred to as MSCs 69 , have properties that may make their use advantageous in cartilage repair. MSCs are abundant in bone marrow 70 (marrow stromal cells), and have been isolated from numerous other tissue sources including adipose tissue, 71 muscle, 72 skin, 73 synovium, 74 periosteum, 75, 76 perichondrium 77 and bone, 78,79 among others. These primitive cells have the capacity to differentiate into cell types of the various mesenchymal tissues and are essential to the natural process of tissue healing. Under certain conditions, MSCs can maintain their multilineage potential with passage, enabling for considerable expansion. 80 (The extent to which this is possible, though, remains somewhat controversial.) Studies also suggest that MSCs may have unique immunosuppressive properties that permit allo-and xeno-transplantation. 81 Since MSCs have the capacity to synthesize both cartilage and bone, they may be well-suited for repair of full-thickness osteochondral lesions.
In contrast to chondrocytes, which represent the terminally differentiated cellular phenotype of articular cartilage, the use of MSCs entails additional layers of complexity in that the cells must first be stimulated toward chondrogenic differentiation, and then stabilized in the chondrocytic phenotype without progression to hypertrophy or dedifferentiation. It is thought that gene transfer might be used as a means to express specific factors that would alter the course of differentiation of MSCs resulting in a stable chondrocytic phenotype and long-term maintenance of hyaline cartilage repair.
Various in vitro systems have been developed to study chondrogenic differentiation in postnatal, mammalian bone-marrow derived cells. 80, [82] [83] [84] In these systems, the role of BMPs and TGF-b's as chondroinductive proteins has been well established. Following this, several studies have shown that transfer of the cDNAs encoding these factors into mesenchymal progenitor cells can likewise be used to induce specific differentiation pathways, depending on culture conditions. Ahrens et al 85 showed that following stable transfection of plasmid DNA encoding either BMP-2 or BMP-4 into the mesenchymal progenitor cell line C3H10T1/2 grown in monolayer, osteogenic differentiation was primarily observed accompanied in some cells by development into adipocytes and chondrocytes. Conversely, delivery of the BMP-2 cDNA into C3H10T1/2 cells subsequently incorporated into micromass culture was found to induce chondrogenic differentiation throughout the aggregate. 86, 87 Similar results were obtained following adenoviral-mediated delivery of TGF-b1 or BMP-2 into human mesenchymal progenitor cells isolated from bone marrow. Human MSCs transduced to express human BMP-2 were found to form ectopic bone and cartilage following injection into mice. 88 These reports support the concept that the delivery and expression of cDNAs encoding chondroinductive proteins can be used as a means to influence the differentiation of MSCs; they also emphasize the importance of biological context. Recently, Palmer et al 89 have performed studies to begin to define the parameters critical to gene-induced chondrogenesis of bone Gene therapy in the repair of articular cartilage SB Trippel et al marrow-derived MSCs using a pellet culture system. This work confirmed the potency of cDNAs for BMP-2 and TGF-b1 (Figure 2 ), but found that efficient chondrogenesis only occurred within a window of protein production. That a threshold level of growth factor synthesis is required to achieve stimulation would be expected; however, these studies imply that overproduction of certain proteins can be inhibitory to chondrogenic differentiation. 89 The concept of an upper limit of transgenic expression is somewhat of a departure in thinking from most gene therapy applications, but may prove to be critical with the use of MSCs in cartilage repair.
MSCs appear reasonably receptive to transduction with recombinant adenoviral vectors, [90] [91] [92] retrovirus, 33, 93 lentivirus and AAV (unpublished observation). Currently, several laboratories are studying means to apply this technology to MSCs in vivo. Clearly, methods that involve the least external manipulation of cells and tissues would be preferable to elaborate and expensive ex vivo strategies. Several strategies are being explored that may enable direct, gene-induced stimulation of MSCs in osteochondral defects in vivo. Perhaps the simplest route is by delivery of recombinant vectors directly into osteochondral lesions, whereupon infiltrating cells acquire the transgene and locally synthesize and secrete the gene products. In this scenario, targeting of gene transfer specifically to MSCs may not be necessary, only to nucleated cells which are capable of synthesizing a gene product. These cells would then create within the defect a microenvironment enriched for a specific chondroinductive protein that would stimulate neighboring MSCs in a paracrine fashion. Toward this direction, it was found that delivery of a liquid suspension of recombinant AAV onto a freshly generated osteochondral defect in rabbits provided measurable transgenic expression within the repair tissue formed in the lesion. 51 Similarly, implantation of three-dimensional matrices preloaded with a gene delivery vehicle into a defect would localize the vector to the lesion while forming a support structure for the attachment of infiltrating cells. Hydrated collagen-glycosaminoglycan matrices containing adenoviral vectors have been found to promote localized transgene expression in vivo following implantation into osteochondral defects in rabbit knees. Pascher et al 94 have recently shown that when fresh bone marrow aspirates from rabbits are mixed with solutions of recombinant adenovirus and then allowed to coagulate, nucleated cells within the formed clot will acquire and express the transgene. By allowing the bone marrow clot to form in the appropriate size and shaped vessel, a semisolid is formed that is completely native to the donor and amenable to implantation. Delivery of marker genes in this manner to osteochondral defects of rabbits was found to enable high-level expression within the defect for several weeks. 94 Mason et al 95 have begun to examine the potential of delivering genetically modified MSCs through tissue engineering methods. In these experiments, primary mesenchymal progenitors derived from rabbit periosteum were transduced with a retrovirus to express human BMP-7 and neomycin phosphotransferase. Following positive selection and expansion in culture, the modified cells were seeded into bioresorbable polymer scaffolds, which were later implanted into osteochondral defects in allogenic rabbits. 96 Relative to control groups, rabbits receiving the grafts with cells expressing BMP-7 showed improved regeneration of bone and cartilage at 8 and 12 weeks postimplant. In an extension of this work, the authors recently compared delivery of the cDNA for sonic hedgehog and BMP-7 using the same experimental approach. 97 Both gene products were effective in improving the quality of the repair over controls. Defects receiving the SHH gene were initially slower to form subchondral bone than those with BMP-7; however, at the end of the 12-week experiment, the overall repair was significantly superior.
Gelse et al 98 have devised a simpler approach to study gene-induced chondrogenesis. MSCs were isolated from rib perichondrium and adenovirally transduced to express either BMP-2 or IGF-1. The cells were then suspended in fibrin glue and delivered to partial thickness lesions in the patellar groove of rat femurs. Relative to naïve and Ad.LacZ controls, which generated fibrous repair tissue, defects receiving the BMP-2-or IGF-1-producing cells generated repair tissue morphologically consistent with hyaline cartilage and contained high levels of collagen type II and proteoglycan. Although defects receiving the BMP-2 cells had greater cellularity and increased proteoglycan content, the majority of the joints showed signs of ectopic bone formation and osteophytes. These were not found in joints that received the MSCs expressing IGF-1. Gene therapy in the repair of articular cartilage SB Trippel et al
Conclusions
The previous sections summarize research progress toward the development of gene-based treatments for damaged articular cartilage. Relative to progress in other musculoskeletal applications discussed in this paper, such as arthritis and fracture repair, studies of genetic therapies for cartilage repair are somewhat less advanced. This is perhaps understandable due to the intrinsic complexities of treating this tissue. Despite this, it has been shown that exogenous cDNAs can be delivered to joint tissues and cartilaginous defects by a number of methods, and that transgenes can be expressed for extended intervals. The results of recent efficacy studies provide evidence that delivery of certain stimulatory gene products can be used to elicit favorable biological responses in vivo. Much work remains, though, to establish the proper gene(s) and gene/cell delivery methods for achieving effective long-term repair of articular cartilage. Further studies should provide a clearer picture of the functional boundaries of these applications and the parameters critical to success. An area that has received little attention is that of regulated transgenic expression. One reason is that it has yet to be determined how much expression is required and for how long. Once this is more clearly established, steps can be taken to more finely tune the process through the incorporation of sophisticated promoter systems. In the process of preclinical evaluation of experimental methods of cartilage treatment and repair, a major obstacle exists in the choice of animal models with genuine relevance to human disease. Smaller mammals such as rats and rabbits offer the capacity for increased sample size, but the chondral layer on these animals is quite thin, and they have a tendency for self-repair. Given the elective nature of medical treatments for cartilage repair, and the risks associated with gene delivery (perceived or otherwise), a prudent pathway to eventual clinical study in humans may be through veterinary medicine. Large animals such as horses and dogs have joints that are proportionally similar to humans, with articular cartilage of more comparable depth. Further, these animals develop actual clinical disease analogous to that found in humans. Since many of the gene products implicated for use in treatment have the potential for generating significant side effects, it may be best to first establish a sustained track record of safety and long-term clinical efficacy in this arena prior to human testing.
